Formulation and pharmacokinetic evaluation of an asulacrine nanocrystalline suspension for intravenous delivery

International Journal of Pharmaceutics

Volumn 367, Issue 1-2, 2009, Pages 179-186

  Ganta, Srinivas ^a   Paxton, James W ^a   Baguley, Bruce C ^b   Garg, Sanjay ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Asulacrine; Dissolution; High pressure homogenization; Nanosuspension; Pharmacokinetics; Tissue distribution

Indexed keywords

ANTINEOPLASTIC AGENT; ASULACRINE; NANOPARTICLE; SN 21407; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CHEMICAL PROCEDURES; CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG HALF LIFE; DRUG SOLUBILITY; DRUG STABILITY; HEART; HIGH PRESSURE HOMOGENIZATION PROCESS; KIDNEY; LIVER; LUNG; MALE; MOUSE; NONHUMAN; PLASMA; PRIORITY JOURNAL; X RAY DIFFRACTION;

AMSACRINE; ANIMALS; ANTINEOPLASTIC AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CRYSTALLIZATION; DRUG COMPOUNDING; DRUG STABILITY; DRUG STORAGE; INJECTIONS, INTRAVENOUS; MALE; MICE; MICE, INBRED C57BL; MICROSCOPY, ELECTRON, SCANNING; NANOPARTICLES; PARTICLE SIZE; SOLUBILITY; SURFACE PROPERTIES; SUSPENSIONS; TISSUE DISTRIBUTION;

EID: 58249109448     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2008.09.022     Document Type: Article

References (33)

1. Andes D. In vivo pharmacodynamics of antifungal drugs in treatment of candidiasis. Antimicrob. Agents Chemother. 47 (2003) 1179-1186
2. Baguley B.C. The possible role of electron-transfer complexes in the antitumour action of amsacrine analogues. Biophys. Chem. 35 (1990) 203-212
3. Baguley B.C., Denny W.A., Atwell G.J., Finlay G.J., Rewcastle G.W., Twigden S.J., and Wilson W.R. Synthesis, antitumor activity, and DNA binding properties of a new derivative of amsacrine, N-5-dimethyl-9-[(2-methoxy-4-methylsulfonylamino)phenylamino]-4-acridinecarboxamide. Cancer Res. 44 (1984) 3245-3251
4. Boedeker B.H., Logeski E., Kline M., and Haynes D. Ultra-long duration local anesthesia produced by injection of lecithin-coated tetracaine microcrystals. J. Clin. Pharmacol. 34 (1994) 699-702
5. Böhm B.H., and Muller R.H. Lab-scale production unit design for nanosuspensions of sparingly soluble cytotoxic drugs. Pharm. Sci. Tech. Today 2 (1999) 336-339
6. Buchmann S., Fischli W., Thiel F.P., and Alex R. Aqueous suspension, an alternative intravenous formulation for animal studies. Eur. J. Pharm. Biopharm. 42 (1996) S10
7. Cain B.F., Atwell G.J., and Denny W.A. Potential antitumor agents. 16. 4′-(Acridin-9-ylamino)methanesulfonanilides. J. Med. Chem. 18 (1975) 1110-1117
8. Clement M., Pugh W., and Parikh I. Tissue distribution and plasma clearance of a novel microcrystalline-coated flurbiprofen formulation. Pharmacologist 34 (1992) 204
9. Covey J.M., Kohn K.W., Kerrigan D., Tilchen E.J., and Pommier Y. Topoisomerase II-mediated DNA damage produced by 4′-(9-acridinylamino)-methanesulfon-m-anisidide and related acridines in L1210 cells and isolated nuclei: relation to cytotoxicity. Cancer Res. 48 (1988) 860-865
10. Ganta S., Paxton J.W., Baguley B.C., and Garg S. Development and validation of bioanalytical method for the determination of asulacrine in plasma by liquid chromatography. J. Pharm. Biomed. Anal. 46 (2008) 386-390
11. Gao L., Zhang D., Chen M., Duan C., Dai W., Jia L., and Zhao W. Studies on pharmacokinetics and tissue distribution of oridonin nanosuspensions. Int. J. Pharm. 355 (2008) 321-327
12. Hardy J.R., Harvey V.J., Paxton J.W., Evans P., Smith S., Grove W., Grillo-Lopez A.J., and Baguley B.C. Phase I trial of the amsacrine analogue 9-({2-methoxy-4-[(methylsulfonyl)amino]-phenyl}]amino)-N,5-dimethyl-4-acridinecarboxamide (CI-921). Cancer Res. 48 (1988) 6593-6596
13. Hintz R.J., and Johnson K.C. The effect of particle size distribution on dissolution rate and oral absorption. Int. J. Pharm. 51 (1989) 9-17
14. Jacobs C., and Muller R.H. Production and characterization of a budesonide nanosuspension for pulmonary administration. Pharm. Res. 19 (2002) 189-194
15. Lipinski C. Poor aqueous solubility-an industry wide problem in drug discovery. Am. Pharm. 5 (2002) 82-85
16. Lipinski C.A., Lombardo F., Dominy B., and Feeney P. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 23 (1997) 3-25
17. Liversidge G.G., and Cundy K.C. Particle size reduction for improvement of oral bioavailability of hydrophobic drugs: I. Absolute oral bioavailability of nanocrystalline danazol in beagle dogs. Int. J. Pharm. 125 (1995) 91-97
18. Maeda H., and Matsumura Y. Tumoritropic and lymphotropic principles of macromolecular drugs. Crit. Rev. Ther. Drug Carrier Syst. 6 (1989) 193-210
19. Manjunath K., and Venkateswarlu V. Pharmacokinetics, tissue distribution and bioavailability of clozapine solid lipid nanoparticles after intravenous and intraduodenal administration. J. Control. Release 107 (2005) 215-228
20. Merisko-Liversidge E., Sarpotdar P., Bruno J., Hajj S., Wei L., Peltier N., Rake J., Shaw J., Pugh S., Polin L., Jones J., Corbett T., Cooper E., and Liversidge G. Formulation and antitumor activity evaluation of nanocrystalline suspensions of poorly soluble anticancer drugs. Pharm. Res. 13 (1996) 272-278
21. Moghimi S.M., Hunter A.C., and Murray J.C. Longcirculating and target-specific nanoparticles: theory to practice. Pharmacol. Rev. 53 (2001) 283-381
22. Mukherjee S., Ghosh R.N., and Maxfield F.R. Endocytosis Physiol. Rev. 77 (1997) 759-803
23. Muller R.H., Jacobs C., and Kayser O. Nanosuspensions as particulate drug formulations in therapy 'rationale' for development and what we can expect for the future. Adv. Drug Deliv. Rev. 47 (2001) 3-19
24. Muller R.H., and Keck C.M. Challenges and solutions for the delivery of biotech drugs-a review of drug nanocrystal technology and lipid nanoparticles. J. Biotechnol. 113 (2004) 151-170
25. Muller R.H., and Peters K. Nanosuspensions for the formulation of poorly soluble drugs: I. Preparation by a size-reduction technique. Int. J. Pharm. 160 (1998) 229-237
26. Patravale V.B., Date A.A., and Kulkarni R.M. Nanosuspensions: a promising drug delivery strategy. J. Pharm. Pharmacol. 56 (2004) 827-840
27. Peters K., Leitzke S., Diederichs J., Borner K., Hahn H., Muller R., and Ehlers S. Preparation of a clofazimine nanosuspension for intravenous use and evaluation of its therapeutic efficacy in murine Mycobacterium avium infection. J. Antimicrob. Chemother. 45 (2000) 77-83
28. Rabinow B.E. Nanosuspensions in drug delivery. Nat. Rev. Drug Discov. 3 (2004) 785-796
29. Rosario P., Claudio B., Piera F., Adriana M., Antonina P., and Giovanni P. Eudragit RS100 nanosuspensions for the ophthalmic controlled delivery of ibuprofen. Eur. J. Pharm. Sci. 16 (2002) 53-61
30. Schneider E., Darkin S.J., Lawson P.A., Ching L.-M., Ralph R.K., and Baguley B.C. Cell line selectivity and DNA breakage properties of the antitumour agent N-[2-(Dimethylamino)ethyl]acridine-4-carboxamide: role of DNA topoisomerase II. Eur. J. Cancer Clin. Oncol. 24 (1988) 1783-1790
31. Shenoy D., Little S., Langer R., and Amiji M. Poly(ethylene oxide)-modified poly(beta-amino ester) nanoparticles as a pH-sensitive system for tumortargeted delivery of hydrophobic drugs: part 2. In vivo distribution and tumor localization studies. Pharm. Res. 22 (2005) 2107-2114
32. Sklarin N., Wiernik P., Grove W., Benson L., Mittelman A., Maroun J., Stewart J., Robert F., Doroshow J., Rosen P., Jolivet J., Ruckdeschel J.C., Robert N.J., Velez-Garci{dotless}a E., Bergsagel D.E., Panasci L.C., Merwe A.M., Longueville J.J., Leiby J., and Kowal C.D. A phase II trial of CI-921 in advanced malignancies. Invest. New Drugs 10 (1992) 309-312
33. Storm G., Belliot S.O., Daemen T., and Lasic D.D. Surface modification of nanoparticles to oppose uptake by the mononuclear phagocyte system. Adv. Drug Deliv. Rev. 17 (1995) 31-48